Promising new clinical data for an experimental COVID-19 treatment hints at a secondary but possibly more important takeaway for investors: if this neutralizing antibody treatment works, so will the coronavirus vaccines that are in development.
MarketWatch.com - Top Stories, MarketWatch
Thu, 10/01/2020 - 12:03pm
Promising new clinical data for an experimental COVID-19 treatment hints at a secondary but possibly more important takeaway for investors: if this neutralizing antibody treatment works, so will the coronavirus vaccines that are in development.